Guangmin Mao1,2,3, Xiu-Hua Shi1,2,4, Xiaofang Wang1,2, Xiaomeng Zhang1,2, Xingxing Chen1,2, Jinli Ma1,2, Xiaoli Yu1,2, Zhen Zhang1,2, Xiaomao Guo1,2. 1. Department of Radiation Oncology, Fudan University Shanghai Cancer Center, Fudan University, Shanghai 200032, China. 2. Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China. 3. Department of Radiation Oncology, Longhua Hospital Shanghai University of Traditional Chinese Medicine, Shanghai 200032, China. 4. Department of Radiation Oncology, The No. 2 People's Hospital of Wuhu City, Wuhu, Anhui Province, China.
Abstract
BACKGROUND: The purpose of this study was to describe the clinicopathological characteristics of breast DCIS in Chinese women and compare with that of patients in western countries. METHOD: From December 2005 to December 2015, 617 women diagnosed with pure DCIS after surgery at our institution were enrolled, and the clinicopathological characteristics were described. RESULTS: In this study, the percentage of patients detected on screening, diagnosed at ≤50 years of age, with tumor size ≤2.0 cm, and with low-intermediate grade was 39.4%, 56.7%, 72.6%, and 77.4%, respectively, as compared to 50-80%, 20-30%, 70-90%, and 40-60% in published reports from western countries. The percentage of ER-positive patients was 76.3% in this study, which is similar to the mean expression rate of ER (mean: 68.7%, range: 49-96.6%) reported previously. CONCLUSIONS: The clinicopathological characteristics of Chinese DCIS patients include less detection on screening, younger age at diagnosis, and more low-intermediate nuclear grade.
BACKGROUND: The purpose of this study was to describe the clinicopathological characteristics of breast DCIS in Chinese women and compare with that of patients in western countries. METHOD: From December 2005 to December 2015, 617 women diagnosed with pure DCIS after surgery at our institution were enrolled, and the clinicopathological characteristics were described. RESULTS: In this study, the percentage of patients detected on screening, diagnosed at ≤50 years of age, with tumor size ≤2.0 cm, and with low-intermediate grade was 39.4%, 56.7%, 72.6%, and 77.4%, respectively, as compared to 50-80%, 20-30%, 70-90%, and 40-60% in published reports from western countries. The percentage of ER-positive patients was 76.3% in this study, which is similar to the mean expression rate of ER (mean: 68.7%, range: 49-96.6%) reported previously. CONCLUSIONS: The clinicopathological characteristics of Chinese DCIS patients include less detection on screening, younger age at diagnosis, and more low-intermediate nuclear grade.
Authors: Fredrik Wärnberg; Hans Garmo; Stefan Emdin; Veronica Hedberg; Linda Adwall; Kerstin Sandelin; Anita Ringberg; Per Karlsson; Lars-Gunnar Arnesson; Harald Anderson; Karin Jirström; Lars Holmberg Journal: J Clin Oncol Date: 2014-10-13 Impact factor: 44.544
Authors: Elizabeth M Ward; Carol E DeSantis; Chun Chieh Lin; Joan L Kramer; Ahmedin Jemal; Betsy Kohler; Otis W Brawley; Ted Gansler Journal: CA Cancer J Clin Date: 2015-10-02 Impact factor: 508.702
Authors: H Bartelink; J C Horiot; P Poortmans; H Struikmans; W Van den Bogaert; I Barillot; A Fourquet; J Borger; J Jager; W Hoogenraad; L Collette; M Pierart Journal: N Engl J Med Date: 2001-11-08 Impact factor: 91.245
Authors: Irene L Wapnir; James J Dignam; Bernard Fisher; Eleftherios P Mamounas; Stewart J Anderson; Thomas B Julian; Stephanie R Land; Richard G Margolese; Sandra M Swain; Joseph P Costantino; Norman Wolmark Journal: J Natl Cancer Inst Date: 2011-03-11 Impact factor: 13.506
Authors: B Fisher; J Costantino; C Redmond; E Fisher; R Margolese; N Dimitrov; N Wolmark; D L Wickerham; M Deutsch; L Ore Journal: N Engl J Med Date: 1993-06-03 Impact factor: 91.245
Authors: Eileen Rakovitch; Sharon Nofech-Mozes; Wedad Hanna; Frederick L Baehner; Refik Saskin; Steven M Butler; Alan Tuck; Sandip Sengupta; Leela Elavathil; Prashant A Jani; Michel Bonin; Martin C Chang; Susan J Robertson; Elzbieta Slodkowska; Cindy Fong; Joseph M Anderson; Farid Jamshidian; Dave P Miller; Diana B Cherbavaz; Steven Shak; Lawrence Paszat Journal: Breast Cancer Res Treat Date: 2015-06-29 Impact factor: 4.872
Authors: Islam M Miligy; Michael S Toss; Kylie L Gorringe; Andrew H S Lee; Ian O Ellis; Andrew R Green; Emad A Rakha Journal: Br J Cancer Date: 2019-05-08 Impact factor: 7.640